3D Bioprinting: Revolutionizing Breast Cancer Drug Resistance Studies
"Discover how scientists are using 3D bioprinting to create more realistic breast cancer models for better drug screening and personalized medicine."
Breast cancer is a complex disease influenced by its surrounding environment, known as the microenvironment. This microenvironment includes various cells like immune cells, endothelial cells, cancer-associated fibroblasts (CAFs), and adipose-derived mesenchymal stem cells (ADMSCs). Understanding how these components interact is crucial for developing effective treatments.
Traditional two-dimensional (2D) cell cultures have limitations in replicating the complexity of the in vivo tumor environment. As a result, three-dimensional (3D) models are gaining traction, offering a more accurate representation of cell-cell and cell-matrix interactions. Among these, 3D bioprinting stands out as a promising technique to assemble living cells and biomaterials into custom-designed constructs.
Recent research published in ACS Biomaterials Science & Engineering explores the use of 3D bioprinting to create breast cancer models for drug resistance studies. This innovative approach allows scientists to investigate the effects of ADMSCs on breast cancer cells in a more realistic setting, potentially leading to better drug screening and personalized medicine strategies.
Drug Resistance and the Case for 3D Models
Breast cancer is described as the world’s second most frequent cancer in women and is histologically and molecularly heterogeneous. The 2025 review reports that animal models have limited clinical utility and that anticancer drugs often fail in clinical trials, pointing to a gap in preclinical modeling link.springer.com. A 2024 study found that breast cancer cells in different regions of a bioprinted tumor microenvironment showed different chemotherapy sensitivities, highlighting environmentally mediated drug resistance sciencedirect.com. Separately, a 2022 study used drug-resistant MCF-7 spheroids in a 3D-printed hydrogel to quantify anticancer drug efficacy using EC50 measurements .
Modeling Methods and Reproducibility Challenges
A 2021 study noted that breast cancer tissue bioprinting research can suffer from reproducibility problems, particularly because scaffold material properties are uncertain and printing methods are lacking sciencedirect.com. A 2022 paper describes a comparative analysis of 2D cultures, 3D spheroids, bioprinted models, and xenografts, and reports a protocol for alginate-based hydrogel bioink and long-term in-vitro tumor-cell culture ncbi.nlm.nih.gov. The available source material identifies these approaches but does not provide a detailed comparison of their relative performance or limitations.
A Developing Field of Breast Cancer Bioprinting
The supplied sources describe 3D bioprinting as a way to build breast cancer models that mimic aspects of the in-vivo environment, with the stated aim of improving drug-resistance studies and supporting personalized treatment research mystum.com. A 2026 review covers advances in breast cancer bioprinting for modeling, diagnosis, therapeutic testing, and clinical translation mdpi.com. The provided material does not identify specific historical milestones or foundational discoveries.
3D Bioprinting Breast Cancer Models: A Step-by-Step Look
The study utilized 3D bioprinting to construct models with breast cancer cells (21PT, HER2+) in the middle and ADMSCs surrounding them, mimicking the in vivo structure of a tumor. These constructs were created using dual hydrogel-based bioinks, allowing for precise placement of different cell types.
- Reduced Apoptosis: The percentage of cleaved Caspase-3 positive cells, indicating apoptosis (cell death), was significantly lower in the 3D bioprinted constructs with ADMSCs compared to cancer cells alone, especially at low DOX doses.
- ADMSC Thickness Matters: Increasing the thickness of the ADMSC layer further enhanced drug resistance, suggesting that ADMSCs provide a protective effect to cancer cells.
- LOX Involvement: Both ADMSCs and 21PT cells expressed lysyl oxidase (LOX), an enzyme involved in collagen cross-linking and known to play a role in cancer progression. Inhibition of LOX enhanced DOX sensitivity.
Recent Reviews and Model Technologies
A review on breast cancer bioprinting focuses on modeling the tumor microenvironment (TME), metastasis, and drug screening doi.org. Another review describes bioengineered in-vitro 3D cancer models and reports that 3D bioprinting, microfluidics, and multi-organ-on-a-chip systems have expanded their use in toxicity screening and drug-response prediction doi.org. A separate 2026 review discusses 3D bioprinting for breast cancer modeling, diagnosis, therapeutic testing, and clinical translation . The supplied abstract for the breast cancer TME review also identifies angiogenesis and metastasis as contributors to breast cancer mortality and says co-cultures of cancer and stromal cells are important for recreating realistic TMEs .
Potential, Limitations, and Translational Relevance
The supplied review describes 3D bioprinting technologies for modeling the breast cancer tumor microenvironment and considers their potential in drug screening. It also examines their advantages and limitations and outlines future directions intended to improve model fidelity and translational relevance advanced.onlinelibrary.wiley.com. The available source summary does not provide specific comparative results or name particular advantages and limitations.
The Future of Cancer Research: 3D Bioprinting and Personalized Medicine
This study underscores the potential of 3D bioprinting to revolutionize cancer research by creating more realistic and predictive tumor models. By incorporating key components of the tumor microenvironment, such as ADMSCs, these models can better mimic the complex interactions that influence drug response.
Recreating Tumor Biology for Drug Screening
A review reports that newer 3D bioprinting technologies have been used to create bioengineered, organotypic tumor structures that aim to mimic human tissue and its microenvironment. It also describes these models as capable of supporting drug-response studies in high-throughput screening settings pmc.ncbi.nlm.nih.gov. The supplied summary does not specify how closely these models reproduce human tumors or identify broader systemic challenges.
Furthermore, the ability to control parameters like ADMSC layer thickness allows researchers to investigate the impact of obesity and other microenvironmental factors on drug resistance. The identification of LOX as a potential target to enhance drug sensitivity opens new avenues for therapeutic intervention.
As 3D bioprinting technology advances, it promises to play an increasingly important role in personalized medicine, enabling the development of tailored cancer treatments based on the unique characteristics of individual tumors and their microenvironment.